Over the course of five years, WIND will collect rich, multidimensional data, including clinical records, imaging results, biomarker data, and patient-reported outcome measures (PROMs). This comprehensive dataset will provide unparalleled insights into PSC progression and help identify factors that influence disease outcomes.
Next Steps: How Data Can be Used and Why it Matters
The WIND-PSC study is more than a data collection effort—it’s a catalyst for innovation. One of its key goals is to create an external control group of untreated PSC patients, which can serve as a benchmark in future clinical trials. This approach allows researchers to evaluate the effectiveness of new therapies without relying on traditional placebo groups.
By building what’s known as an “external control (or placebo) arm,” WIND-PSC will enable researchers to identify historical patient profiles that closely match those receiving new treatments. Comparing the outcomes between these groups provides a powerful way to assess treatment impact and streamline trials.
The insights gained from this rich, real-world dataset have immense potential to accelerate the development of effective therapies and improve the lives of individuals living with PSC.
